fda approved semaglutide for weight loss US approves drug Wegovy to prevent cardiovascular events Medicine Guide – Tagged "FDA

Common Mistakes To Avoid Some of the most frequent transition mistakes include: Skipping the washout period, which may increase nausea Starting tirzepatide too high, especially if stepping off a high semaglutide dose Assuming similar milligram amounts mean similar potency Titrating too quickly Changing doses without medical supervision Following a structured plan helps avoid these issues

This is expected, not pathological, and rarely requires additional intervention beyond giving the new medication time to reach steady state

Trials have shown that the higher dose of Wegovy resulted in a 20.7% weight reduction on average about the same as Lilly's Zepbound jab

Plan for an initial adaptation period, a mid-term acceleration phase, and a long-term sustained results phase

This plateau is common with any weight loss approach and doesnt mean the medication has failed

Youll learn strategies to support your metabolism, manage appetite, and maintain weight loss long-term